ACLARIS THERAPEUTICS Trademark

Trademark Overview


On Friday, September 1, 2023, a trademark application was filed for ACLARIS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ACLARIS THERAPEUTICS trademark a serial number of 98161577. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, August 21, 2024. This trademark is owned by Aclaris Therapeutics, Inc.. The ACLARIS THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

anti-inflammatories; pharmaceutical preparations for dermatological, gastro-intestinal, autoimmune, immune system, skin, oncological, immuno-inflammatory, musculoskeletal, respiratory, central nervous system, kidney diseases, cardiovascular, endocrine, tissue and organ, ocular, ophthalmological, metabolic, genitourinary, urological, hepatic, otolaryngology, hematologic, genetic, and bone diseases and disorders; pharmaceutical preparations for the treatment of transplant rejection, graft-versus-host disease, vasculitis, myositis, myopathies, diabetes, allergies, asthma, and hair loss
aclaris therapeutics

General Information


Serial Number98161577
Word MarkACLARIS THERAPEUTICS
Filing DateFriday, September 1, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, August 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of lower case letters "ACLARIS" centered over smaller capital letters "THERAPEUTICS," which are placed over on the right side of a partial circle design comprised of four segmented curved lines.
Goods and Servicesanti-inflammatories; pharmaceutical preparations for dermatological, gastro-intestinal, autoimmune, immune system, skin, oncological, immuno-inflammatory, musculoskeletal, respiratory, central nervous system, kidney diseases, cardiovascular, endocrine, tissue and organ, ocular, ophthalmological, metabolic, genitourinary, urological, hepatic, otolaryngology, hematologic, genetic, and bone diseases and disorders; pharmaceutical preparations for the treatment of transplant rejection, graft-versus-host disease, vasculitis, myositis, myopathies, diabetes, allergies, asthma, and hair loss
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 27, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAclaris Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWayne, PA 19087

Trademark Events


Event DateEvent Description
Tuesday, September 5, 2023NEW APPLICATION ENTERED
Thursday, November 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, September 27, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 28, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, November 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 7, 2024NON-FINAL ACTION WRITTEN
Tuesday, May 7, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 7, 2024NON-FINAL ACTION E-MAILED
Tuesday, April 30, 2024ASSIGNED TO EXAMINER
Wednesday, August 21, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, August 21, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE